Risk of Incident Inflammatory Bowel Disease in New Users of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Dependent Glucose Co-Transporter 2 Inhibitors in the FDA Sentinel System

Previous studies reported inconsistent findings of the risk of inflammatory bowel disease (IBD: Crohn’s disease [CD], ulcerative colitis [UC], and indeterminate colitis) following dipeptidyl peptidase-4 inhibitors (DPP-4i) exposure. 

This poster describes characteristics of new users of DPP-4i and sodium glucose cotransporter 2 inhibitors (SGLT-2i) and to estimate the overall risk of incident IBD to inform future inferential analyses. It was presented at the 2024 ISPE Annual Meeting.